Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 62332-233

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 62332-233). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vilazodone-10mg-30s.jpg (Vilazodone 10mg 30s)

This is a medication label for a batch of Trazodone Hydrochloride tablets. The NDC number, dosage, and storage instructions are provided. It also indicates that the medication should be dispensed with a medication guide for each patient and manufactured by Alembic Pharmaceuticals.*

FDA Label Image

Vilazodone-20mg-30s.jpg (Vilazodone 20mg 30s)

This appears to be a description of a medication called Vilazodone Hydrochloride in tablet form. The tablets are stored at a temperature range of 15-30°C (58-86°F) and each tablet contains 23.3-30 mg of the medication. The manufacturer is Alembic Pharmaceuticals Limited and the medication is dispensed by a pharmacist with a prescription. The text also includes instructions for the manufacturer and a modification guide for each patient.*

FDA Label Image

Vilazodone-40mg-30s.jpg (Vilazodone 40mg 30s)

Description not-available*

FDA Label Image

Vilazodone-fig.jpg (Vilazodone Fig)

FDA Label Image

Figure 3 (Vilazodone Fig3)

This text provides population descriptions and fold change values for different subgroups in terms of age, gender, and renal/hepatic impairment. The fold change values represent the changes relative to the reference group (younger subjects, male subjects, and subjects with normal renal and hepatic function). The text also includes information on the confidence intervals for each subgroup.*

FDA Label Image

Figure 2 (Vilazodone Figr2)

The text describes the impact of Vilazodone on the pharmacokinetics of various drugs and substrates, including CYP3A4, CYP1A2, CYP2A6, CYP2A9, CYP2A19, and P-gp. The data presented include fold changes and 90% confidence intervals for changes in PK and relative changes in AUC, urinary recovery, and plasma concentration for each substrate. The text is a figure caption presenting a chart of this data.*

FDA Label Image

Vilazodone-figur1.jpg (Vilazodone Figur1)

The text is describing a figure depicting the effect of different drugs on the pharmacokinetics of Vilazodone. The drugs include Ethanol, CYP3A4 inhibitors (Ketoconazole), CYP3A4 inducers (Carbamazepine), and Proton Pump inhibitors (Pantoprazole). The figure also shows the change in PK (pharmacokinetics) and AuC (Area under the curve) with respect to a reference. There is also a fold change and a 90% confidence level provided in the figure. No further information is available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.